Nutritional Intervention for Canine Cognitive Dysfunction
In 2016, 38% of U.S. households owned a dog.1 Given this large population of pets, many of whom are aging, practitioners are being presented with more opportunities to examine and assess senior canine patients. Many owners believe it is normal for pets to “slow down” as they age and therefore seldom report mild changes in behavior.2 Yet any change in behavior could be a sign of cognitive dysfunction syndrome (CDS) or of an underlying medical condition. Therefore, veterinarians must be proactive in screening and counseling owners on the importance of reporting behavioral signs.
HOW COMMON IS CDS?
In a 2001 survey of 180 neutered dogs aged between 11 and 16 years, owners reported cognitive impairment in one or more behavioral categories in 28% of the youngest dogs (age 11 to 12 years) and impairment in 2 or more categories in 10% of the same group.3 Of dogs aged 15 or 16 years, 68% were impaired in one or more behavioral categories and 35% in 2 or more categories. A 2010 study using an online validated cognitive questionnaire found a prevalence of CDS of 14.2%. Only 1.9% of these dogs had been diagnosed by their veterinarian.4 Size and breed were not indicative for developing CDS;4 however, the older the pet, the higher probability of having more severe signs.
WHAT ARE THE SIGNS OF CDS?
Dogs with CDS show deficits in memory, learning, spatial awareness, perception, social interactions, and sleeping patterns. The acronym DISHAA can be used to aid in screening and diagnosis of clinical signs:
- Disorientation. Owners may report that their dog stares at the wall, has difficulty navigating around the house, or becomes stuck behind furniture. The dog may be less responsive to verbal cues, unable to localize sounds, and less interested in exploring new toys and smells. Some pets may no longer recognize familiar people or places.
- Changes in Social Interactions. The dog may increase or decrease its interactions with family members. Owners may report that their pets are more irritable or distressed when left alone or that they no longer greet their owners when they come home.
- Changes in Sleep-Wake Cycle. Nighttime pacing or vocalization that interrupts the owners’ sleep may be particularly distressing for owners.
- Loss of Housetraining. Dogs with CDS may no longer signal their need to go outside for elimination, instead choosing different locations inside the house.
- Changes in Activity. While dogs may exhibit overall decreased activity, with advancing CDS they may begin pacing aimlessly and are unable to settle.
- Anxiety. In addition to being more agitated, dogs may be more fearful or worried about stimuli and situations they previously tolerated, such as loud noises, going on walks, walking on certain surfaces, interacting with other dogs or people, or being left home alone.
WHAT CAUSES CDS?
When a patient exhibits any change in behavior, a diagnostic workup is needed to first rule out any medical causes. In one study, 28% of 300 dogs with signs of CDS were found to have a medical problem that may have caused or contributed to the signs.2 For example, dogs with hyperadrenocorticism may exhibit signs similar to those of CDS, such as increased anxiety and loss of housetraining. Dogs with intracranial diseases may exhibit behavioral changes, such as disorientation or changes in interactions with family members.
Pathologic changes in the brain associated with aging include ventricular dilation, decreased frontal and temporal lobe volume, compromised cerebrovascular circulation, neuronal loss, a decline in cholinergic brain function, an increase in toxic free radicals, and deposition of beta-amyloid and hyperphosphorylated tau, all of which might be correlated with a decline in cognitive function.5-9
HOW DOES AGING AFFECT NUTRITION?
In humans and dogs, multiple risk factors have been associated with brain aging, including B vitamin and docosahexaenoic acid (DHA) deficiencies, chronic oxidative stress, low-grade inflammation, and reduced brain glucose metabolism, which contribute to mitochondrial dysfunction, energy deprivation, decreased neuronal function, and cognitive decline.6,10,11
Atrophic gastritis in elderly people has been theorized to interfere with absorption of vitamin B12 and folic acid. It is unclear if a similar process occurs in dogs. In people, supplementation with B vitamins can be helpful. Elderly people with low levels of vitamin B showed improved cognitive function when given a vitamin B supplement.10 Vitamin B12 is needed in the process of forming methionine, which undergoes methylation to form S-adenosyl methionine (SAMe). When the formation of SAMe is limited, the production of phosphatidylcholine, myelin, melatonin, and catecholamines, as well as DNA and RNA synthesis, is also affected. SAMe helps maintain cell membrane fluidity and receptor function, decrease the turnover of monoamine transmitters, and increase the production of the endogenous antioxidant. Another B vitamin, pyridoxine (vitamin B6), is also important for normal brain development, function, and neuronal health and is a cofactor in the synthesis of several neurotransmitters, such as serotonin, noradrenaline, and dopamine.10
THE USE OF DIET TO TREAT CDS
Studies in both laboratory models and clinical trials have demonstrated a beneficial effect of nutrition on improving clinical signs of CDS and slowing the progression of cognitive dysfunction in dogs. The use of combined ingredients (Table 1) to combat oxidative and free radical changes may have a synergistic effect to reduce cognitive decline.16 In one study, dogs fed high-quality commercial diets designed for age, size, or health were 2.8 times less likely to develop CDS than dogs fed low-quality commercial food or table scraps.17 The diets discussed below are commercially available and supported by evidence of clinical effect.
A diet supplemented with antioxidants, vitamins E and C, beta carotene, ascorbic acid, selenium, flavonoids and carotenoids, mitochondrial cofactors DL-alpha-lipoic acid and L-carnitine, and omega-3 fatty acids has been developed for dogs with CDS (Hill’s Prescription Diet® b/d® Canine; hillspet.com). A 2-year study demonstrated a decrease in the rate of cognitive decline with the use of this diet, with the greatest effect seen when combined with behavioral enrichment.17
Studies have demonstrated a reduction in cerebral glucose metabolism in dogs as young as 6 years, which may contribute to brain energy deprivation, decreased neuronal function, and cognitive decline.11 Ketone bodies are the principal alternative source of energy for the brain. Medium-chain triglycerides (MCTs) are converted by the liver to the ketone body beta-hyroxybutyrate for improved energy metabolism and mitochondrial function in the aging brain.16 MCTs may increase the amount of polyunsaturated fatty acids in the parietal cortex of senior dogs.17 In one study, dogs fed a diet supplemented with MCT performed better on cognitive tasks compared with controls.18
A diet supplemented with a “brain protection blend” of ingredients—including B vitamins, antioxidants (vitamins E and C), selenium, DHA, eicosapentaenoic acid, and arginine (Purina Neurocare™; purina.com/purina-pro-plan-veterinary-diets)—has also been demonstrated to improve cognitive function compared with a control diet in a laboratory trial in beagles. In a 3-month clinical trial, client-owned dogs aged 9 to 16 years that had been diagnosed with signs of CDS were fed a diet containing 6.5% MCT in combination with this ingredient blend. These dogs had significant improvement in all 6 categories of DISHAA compared with a control group, in which 4 of 6 categories improved.19 An over-the-counter product (Purina Bright Mind®; purina.com/pro-plan/dogs/bright-mind-dog-food) is also formulated with the “brain protection blend” and 5.5% MCT.
In one study, dogs fed high-quality commercial diets designed for age, size, or health were 2.8 times less likely to develop CDS than dogs fed low-quality commercial food or table scraps.17
THE USE OF NUTRITIONAL SUPPLEMENTS TO TREAT CDS
Nutritional supplements may also be used to improve signs and slow decline of CDS. A commercial supplement (Senilife®; Ceva Animal Health, senilife.com) containing phosphatidylserine, pyridoxine, Gingko biloba, and vitamin E was shown in one small laboratory crossover trial of 9 dogs, and in an open-label trial of 8 dogs with CDS, to improve short-term memory and clinical signs associated with CDS.20 Phosphatidylserine is a phospholipid needed to maintain cell membrane health. It may facilitate neuronal processes and stimulate acetylcholine release and neurotrophic growth. G. biloba improves cerebral blood flow, increases glucose metabolism, has an antioxidative effect, and may be protective against beta-amyloid damage. A supplement containing phosphatidylserine and omega-3 fatty acids, vitamin C, L-carnitine, alpha-lipoic acid, coenzyme Q, and selenium (Activait®; Vet Plus, vetplusglobal.com) has also demonstrated efficacy in improving clinical signs of CDS, including disorientation and sleep, in a placebo-controlled trial of 44 dogs.21
Another supplement marketed for treatment of CDS, SAMe tosylate disulfate, has been shown to improve cognitive function. In a placebo-controlled clinical trial, 36 dogs with CDS that received the SAMe supplement had increased activity and interactivity with their owners.22 Supplementation with SAMe may improve attention and executive function. SAMe also increases central serotonin levels, which may be reduced in senior dogs. Therefore, SAMe should be used cautiously with drugs that increase serotonin levels.
Nutritional supplementation complements the use of medication, behavioral enrichment, and environmental management to treat CDS. Some single-ingredient products may be effective; however, the additive or synergistic effects of ingredients in diets or supplements may provide the most benefit to reduce cognitive decline in canine patients.
1. American Veterinary Medical Association (AVMA) Veterinary Economics Division. AVMA Pet Ownership and Demographics Sourcebook: 2017-2018 Edition. 2018.
2. Madari A, Farbakova J, Katina S, et al. Assessment of severity and progression of canine cognitive dysfunction syndrome using the canine dementia scale (CADES). Appl Anim Behav Sci 2015;171:138-145.
3. Neilson JC, Hart BL, Cliff KD, Ruehl WW. Prevalence of behavioral changes associated with age-related cognitive impairment in dogs. JAVMA 2001;218(11):1787-1791.
4. Salvin HE, McGreevy PD, Sachdev PS, et al. Under diagnosis of canine cognitive dysfunction: a cross-sectional survey of older companion dogs. Vet J 2010;184(3):277-281.
5. Borràs D, Ferrer I, Pumarola M. Age-related changes in the brain of the dog. Vet Pathol 1999;36(3):202-211.
6. Head E, Liu J, Hagen TM, et al. Oxidative damage increases with age in a canine model of human brain aging. J Neurochem 2002;82(2):375-381.
7. Smolek T, Madari A, Farbakova J, et al. Tau hyperphosphorylation in synaptosomes and neuroinflammation are associated with canine cognitive impairment. J Comp Neurol 2016;524(4):874-895.
8. Tapp PD, Siwak CT, Gao FQ, et al. Frontal lobe volume, function, and β-amyloid pathology in a canine model of aging. J Neurosci 2004;24(38):8205-8213.
9. Araujo JA, Nobrega JN, Raymond R, Milgram NW. Aged dogs demonstrate both increased sensitivity to scopolamine and decreased muscarinic receptor density. Pharmacol Biochem Behav 2011;98(2):203-209.
10. Selhub J, Bagley LC, Miller J, Rosenberg IH. B vitamins, homocysteine, and neurocognitive function in the elderly. Am J Clin Nutr 2000;71(2):614S-620S.
11. London ED, Ohata M, Takei H, et al. Regional cerebral metabolic rate for glucose in beagle dogs of different ages. Neurobiol Aging 1983;4(2):121-126.
12. Kidd PM. A review of nutrients and botanicals in the integrative management of cognitive dysfunction. Altern Med Rev
13. Studzinski CM, MacKay WA, Beckett TL, et al. Induction of ketosis may improve mitochondrial function and decrease steady-state amyloid-beta precursor protein (APP) levels in the aged dog. Brain Res 2008;1226:209-217.
14. Taha AY, Henderson ST, Burnham WM. Dietary enrichment with medium chain triglycerides (ac-1203) elevates polyunsaturated fatty acids in the parietal cortex of aged dogs: implications for treating age-related cognitive decline. Neurochem Res 2009;34(9):1619-1625.
15. Pan Y, Kennedy AD, Jönsson TJ, Milgram NW. Cognitive enhancement in old dogs from dietary supplementation with a nutrient blend containing arginine, antioxidants, B vitamins and fish oil. Br J Nutr 2018;119(3):349-358.
16. Katina S, Farbakova J, Madari A, et al. Risk factors for canine cognitive dysfunction syndrome in Slovakia. Acta Vet Scand 2016;58:17.
17. Milgram NW, Head E, Zicker SC, et al. Learning ability in aged beagle dogs is preserved by behavioral enrichment and dietary fortification: a two-year longitudinal study. Neurobiol Aging 2005;26(1):77-90.
18. Pan Y, Larson B, Araujo JA, et al. Dietary supplementation with medium-chain TAG has long-lasting cognition-enhancing effects in aged dogs. Br J Nutr 2010;103(12):1746-1754.
19. Pan Y, Landsberg G, Mougeot I, et al. Efficacy of a therapeutic diet on dogs with signs of cognitive dysfunction syndrome (CDS): a prospective double blinded placebo controlled clinical trial. Front Nutr 2018;5:127.
20. Araujo JA, Landsberg GM, Milgram NW, Miolo A. Improvement of short-term memory performance in aged beagles by a nutraceutical supplement containing phosphatidylserine, ginkgo biloba, vitamin E, and pyridoxine. Can Vet J 2008;49(4):379-385.
21. Osella MC, Del Re G, Odore R, et al. Canine cognitive dysfunction syndrome: prevalence, clinical signs and treatment with a neuroprotective nutraceutical. Appl Anim Behav Sci 2007;105(4):297-310.
22. Rème CA, Dramard V, Kern L, et al. Effect of S-adenosylmethionine tablets on the reduction of age-related mental decline in dogs: a double-blinded, placebo-controlled trial. Vet Ther 2008;9(2):69-82.